drugset / Trial / NCT06658977
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
NaSingle-groupOpen-labelTreatment
Summary
Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial. This study aims to assess whether Triumeq is safe and effective at delaying ALS disease progression when given long term. It is available for participants who have completed the Lighthouse II study. The main measurements are safety, tolerability and survival. The study will go for approximately 2 years.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2025-06-03
- Completion
- 2025-06-03
Outcome
Outcome not reported
Stopped: “This is a rollover study following the Lighthouse II trial; it was scheduled to stop when the LH II trial was stopped/completed. The LH II trial has been prematurely terminated so, likewise, this study has also now been stopped.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 600 mg | — |
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |